Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long ‐term extension studies over 7 years

ConclusionsTofacitinib efficacy/safety were similar in both populations, except TB IR, which was higher in Indian patients but in line with those in bDMARD ‐treated RA patients from high‐risk countries (IR = 0.00‐2.56; TB IR>0.05 [World Health Organization]). Limitations included the small Indian population and baseline differences between populations.

Source: International Journal of Rheumatic Diseases - May 31, 2020 Category: Rheumatology Authors: Arvind Chopra, Vineeta Shobha, Srikantiah Chandrashekara, Sarath C. M. Veeravalli, Reena Sharma, Uppuluri R. Rao, Sapan Pandya, Shrikant Wagh, Jugal K. Kadel, Amit V. Thorat, Charles Adhav, Paul Santos Estrella, Wei Yu, Kenneth Kwok, Ann Wou Tags: ORIGINAL ARTICLE Source Type: research